Program
DAY 1
Wednesday, 27 November 2024
8h30
Registration & welcome coffee
9h10
Welcome Address
9h15
Opening lectures
- Plenary
Chaired by Daniel Larocque, Sanofi
9h15
Discovery and Characterization of Zosurabalpin
Claudia Zampaloni
Senior Principal Scientist
Roche - Switzerland
9h45
Systems-level analyses of human immunity
Petter Brodin
Professor
Imperial college London - United Kingdom
Karolinska Institute - Sweden
10h15
Coffe Break - B2B Meetings
10h45
Track 1: Alternatives to current antibiotics
- Plenary
Chaired by Francesca Bernardini, Evotec & Sébastien Coyne, Aurobac
10h45
Application of phage therapy in infectious diseases
Giuseppe Maccari
Senior Bioinformatician
Toscana Life Sciences - Italy
& Co-founder
Fagoterapia LAB- Italy
11h05
A Human Lung Tissue Model to Study - Pseudomonas aeruginosa Infection and Treatment
Urs Jenal
Swiss Microbiologist and Professor
Biozentrum - University of Basel - Switzerland
11h25
Phage lysins for transformative innovation of the antibiotics market
Yves Briers
CSO
Obulytix - Belgium
11h45
Q&A session
12h00
Lunchbreak - Poster Presentation - B2B Meetings
14h00
Track 2 : Immunotherapies & new biotherapeutics
- Plenary
Chaired by Robbert van der Most, VaxxCellence & Cyril Guyard, Bioaster
14h00
Broad spectrum biotherapies for emergency preparedness
Caroline Ballet
Scientific Project Leader
Fab'entech - France
14h20
The potential of broadly neutralizing antibodies to prevent and treat HIV-1 infection
Florian Klein
Professor and Director
University Hospital of Cologne - Germany
14h40
Breaking new ground - targeting the gut microbiota in systemic autoimmunity
Carina Brune
Pharmacist
University of Münster - Germany
15h00
Targeting Long Non-Coding RNAs with Antisense Oligonucleotides to Enhance Vaccine Response
Stephanie Fanucchi
CSO
Lemba Therapeutics - Netherlands
15h20
Insights into the in vivo mode of action of mono- and bispecific antibodies through kinetic analysis
of affinity and avidity
Anahí Higuera-Rodriguez
Field Application Scientist
Dynamic Biosensors - Germany
15h35
Q&A session
15h50
Coffe Break - B2B Meetings
16h30
Breakthrough innovation Session
- Plenary
Chaired by Fabienne Venet, Hospices Civils de Lyon & Mélanie Denizot, Lyonbiopôle
16h30
The Vaccine Architect: Designing Antigen with Immunological Blueprints
Vincent Pavot
Head of Immunology Platform
Sanofi - France
Coline Sivelle
Protein Engineering Scientist
Sanofi - France
16h50
Exploiting the Complement system for directed therapy against Pseudomonas aeruginosa infections
Aubin Pitiot
Postdoctoral Fellow
Luxembourg Institute of Health - France
17h00
Development of novel genetic vaccine platforms for epidemic preparedness: from the idea to GMP production
Antonella Comforti
Principal Investigator
Takis Biotech - Italy
17h10
New antigenic urinary assay for BK polyomavirus
Etienne Brochot
Professor of Virology
CHU Amiens - France
17h20
New approaches for diagnosis and therapy by phage proteins
Mai Huong Chatain
CSO/CEO
Vetophage - France
17h30
The Cochlin LCCL Domain: A Novel Therapeutic Agent for Enhancing Host Innate Immunity during infection through Efferocytosis
Louise Courcol
PhD student
CIRI - France
17h40
Generation of a pan-specific anti-human influenza A Nanofitin for direct protective effect in respiratory tract
Perrine Jacquot
R&D Project Manager
Affilogics - France
17h50
Better antibodies against membrane proteins thanks to recombinant extracellular vesicles
Vincent Delauzun
Research Scientist
Cytobodx - France
18h00
End of DAY 1
DAY 2
Thursday, 28 November 2024
9h00
Welcome coffee
9h30
Opening lectures
- Plenary
Chaired by
9h30
Progress in TB vaccine discovery and development
Willem Hanekom
Director
Africa Health Research Institute (AHRI) - South Africa
10h00
Shifts in pandemic medical countermeasures – Global Preparedness Monitoring Board
Sylvie Briand
Director
Pandemic and Epidemic Diseases Department
at the World Health Organization (WHO) - France
10h30
Coffe Break - B2B Meetings
11h00
Track 3 : Latest developments in Vaccines
- sponsored by Sanofi
Chaired by Daniel Larocque, Sanofi & Behazine Combadière, Sanofi
11h00
General view of latest vaccine developments by Sanofi and early stage immunology research
Behazine Combadiere
Global head of Early-stage Immunology
Sanofi - France
11h30
Advances in Immunological Memory: The Role of β-Glucan in Innate Immune Modulation
Jessica Quintin
Head of the Immunology of Fungal Infections Unit
Institut Pasteur - France
11h50
Development of the single-shot chikungunya vaccine IXCHIQ
Martina Schneider
Clinical Strategy Manager
Valneva - France
12h10
Q&A session
12h25
Lunch - Poster Presentation - B2B Meetings
14h00
Track 3 : Latest developments in Vaccines
- sponsored by Sanofi
Chaired by Lionel Cupillard, Boehringer Ingelheim Animal Health
14h00
Latest results for Metavac®-RSV, a mucosal bivalent live attenuated vaccine
Julia Dubois
Researcher scientist
Laboratoire VirPath, CIRI - France
14h20
Preparedness & reactiveness in the development of a new Blue Tongue Virus vaccine
Helene Gaude
Project Leader, Veterinary Public Health vaccines development
Boehringer Ingenheim Animal Health – France
14h40
A Novel Vaccine Against Neisseria gonorrhoea
Michael Kowarik
CSO
LimmaTech Biologics – Switzerland
15h00
Q&A session
15h15
Track 4 : Diagnostic Prognostic and theragnostic Biomarkers
- Plenary
Chaired by
15h15
How a multiplex lateral flow immunoassay is helping clinicians worldwide combat antimicrobial resistance
Milovan Stankov-Pugès
CEO
NG Biotech - France
15h35
Unveiling Immune Insights: The Crucial Role of Immune Functional Assays (IFA) in Immunomonitoring
William Mouton
PhD, post-Doc
Hospices Civils de Lyon - France
15h55
Q&A session
16h10
Annoucemment of next year edition
16h20
